Gefitinib, the orally administered tyrosine kinase inhibitor for lung cancer patients harboring the epidermal growth factor receptor (EGFR) mutations across therapy lines (Wu and Shih, 2018). The gene discussed is EGFR; the disease is lung carcinoma.